Mezzion Pharma메지온
140410 · KOSDAQ · ₩140410 · 메지온
₩52,600▼ ₩1,300 (2.41%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩7.9B | ₩8.6B | ₩32B | ₩31B | ₩27B |
| Operating income | −₩17B | −₩14B | −₩14B | −₩23B | −₩17B |
| Net income | −₩35B | −₩19B | −₩13B | −₩36B | −₩14B |
| Net income to shareholders | −₩35B | −₩19B | −₩13B | −₩36B | −₩14B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩98B | ₩74B | ₩92B | ₩54B | ₩84B |
| Current assets | ₩46B | ₩42B | ₩74B | ₩46B | ₩64B |
| Cash and equivalents | ₩26B | ₩14B | ₩40B | ₩29B | ₩24B |
| Total liabilities | ₩81B | ₩28B | ₩31B | ₩28B | ₩21B |
| Current liabilities | ₩80B | ₩27B | ₩30B | ₩26B | ₩18B |
| Borrowings | ₩9.9B | — | — | — | — |
| Total equity | ₩17B | ₩46B | ₩61B | ₩26B | ₩63B |
| Shareholders' equity | ₩17B | ₩46B | ₩61B | ₩26B | ₩63B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩17B | −₩18B | −₩11B | −₩12B | −₩15B |
| Capital spending | −₩137M | −₩590M | — | — | — |
| Free cash flow | −₩17B | −₩19B | −₩11B | −₩12B | −₩15B |
Consolidated where available. Amounts in won.
Also known as: Mezzion Pharma / 메지온 / 140410 / KRX:140410
Source: KRX statistical information